Immunization Schedule

• 

  Subject Areas on Research

  • A canarypox vaccine expressing multiple human immunodeficiency virus type 1 genes given alone or with rgp120 elicits broad and durable CD8+ cytotoxic T lymphocyte responses in seronegative volunteers. 
  • A comparative evaluation of nasal and parenteral vaccine adjuvants to elicit systemic and mucosal HIV-1 peptide-specific humoral immune responses in cynomolgus macaques. 
  • A comparison of 2 influenza vaccine schedules in 6- to 23-month-old children. 
  • A major barrier to universal hepatitis B immunization of infants. 
  • A program for eradication of hepatitis B from Taiwan by a 10-year, four-dose vaccination program. 
  • A shortened interval between vaccinations with the trivalent inactivated influenza vaccine increases responsiveness in the aged. 
  • AIDS Vaccine Research Subcommittee (AVRS) Consultation: Early-Life Immunization Strategies against HIV Acquisition. 
  • Achieving Potent Autologous Neutralizing Antibody Responses against Tier 2 HIV-1 Viruses by Strategic Selection of Envelope Immunogens. 
  • Addressing the vaccine confidence gap. 
  • Advisory Committee on Immunization Practices recommended immunization schedule for adults aged 19 years or older - United States, 2014. 
  • Advisory committee on immunization practices recommended immunization schedule for adults aged 19 years or older--United States, 2015. 
  • Analysis of factors influencing vaccine uptake: perspective from Spain. 
  • Antibody to native human immunodeficiency virus type 1 envelope glycoproteins induced by IIIB and MN recombinant gp120 vaccines. The NIAID AIDS Vaccine Evaluation Group. 
  • Boosting with Subtype C CN54rgp140 Protein Adjuvanted with Glucopyranosyl Lipid Adjuvant after Priming with HIV-DNA and HIV-MVA Is Safe and Enhances Immune Responses: A Phase I Trial. 
  • Brief Report: Prediction of Serum HIV-1 Neutralization Titers After Passive Administration of VRC01. 
  • Cocooning infants: Tdap immunization for new parents in the pediatric office. 
  • Comparative study of the immunogenicity and safety of two dosing schedules of hepatitis B vaccine in neonates. 
  • Comparison of acellular pertussis-diphtheria-tetanus toxoids and Haemophilus influenzae type b vaccines administered separately vs. combined in younger vs. older toddlers. 
  • Comparison of the epidemiology and cost of Haemophilus influenzae type b disease in five western countries. 
  • Completeness of Human Papilloma Virus Vaccination: A Systematic Review. 
  • Containment of simian immunodeficiency virus infection in vaccinated macaques: correlation with the magnitude of virus-specific pre- and postchallenge CD4+ and CD8+ T cell responses. 
  • Control of a mucosal challenge and prevention of AIDS by a multiprotein DNA/MVA vaccine. 
  • Controversies in immunization. 
  • Correlates of human papillomavirus (HPV) vaccination initiation and completion among 18-26 year olds in the United States. 
  • Cost-effectiveness evaluation of measles immunization strategies on a college campus. 
  • Cross-reactivity of HIV vaccine responses and the microbiome. 
  • DNA-MVA-protein vaccination of rhesus macaques induces HIV-specific immunity in mucosal-associated lymph nodes and functional antibodies. 
  • Development and application of a multiplex assay for the simultaneous measurement of antibody responses elicited by common childhood vaccines. 
  • Do mobile phone-based reminders and conditional financial transfers improve the timeliness of childhood vaccinations in Tanzania? Study protocol for a quasi-randomized controlled trial. 
  • Effectiveness of catch-up human papillomavirus vaccination on incident cervical neoplasia in a US health-care setting: a population-based case-control study. 
  • Efficacy of DNA and fowlpox virus priming/boosting vaccines for simian/human immunodeficiency virus. 
  • Elimination of Perinatal Hepatitis B: Providing the First Vaccine Dose Within 24 Hours of Birth. 
  • Enhanced Immune Responses to HIV-1 Envelope Elicited by a Vaccine Regimen Consisting of Priming with Newcastle Disease Virus Expressing HIV gp160 and Boosting with gp120 and SOSIP gp140 Proteins. 
  • Evaluating human papillomavirus vaccination programs. 
  • Evidence for a 4-dose vaccine schedule for human rabies post-exposure prophylaxis in previously non-vaccinated individuals. 
  • Family physician acceptance of universal hepatitis B immunization of infants. 
  • Guidelines for immunizations in patients with inflammatory bowel disease. 
  • HIV-1 gp120 vaccine induces affinity maturation in both new and persistent antibody clonal lineages. 
  • HPV antibody levels and clinical efficacy following administration of a prophylactic quadrivalent HPV vaccine. 
  • Hapten-induced primary and memory humoral responses are inhibited by the infusion of anti-CD20 monoclonal antibody (IDEC-C2B8, Rituximab). 
  • Harmony on the second dose of measles vaccine. 
  • Human lymphocyte proliferation responses following primary immunization with rabies vaccine as neoantigen. 
  • Immune responses to human immunodeficiency virus (HIV) type 1 induced by canarypox expressing HIV-1MN gp120, HIV-1SF2 recombinant gp120, or both vaccines in seronegative adults. NIAID AIDS Vaccine Evaluation Group. 
  • Immunization of rhesus macaques with a polyvalent DNA prime/protein boost human immunodeficiency virus type 1 vaccine elicits protective antibody response against simian human immunodeficiency virus of R5 phenotype. 
  • Immunization with trivalent inactivated influenza vaccine in partially immunized toddlers. 
  • Immunizations for preteens. 
  • Immunogenicity and Optimal Timing of 13-Valent Pneumococcal Conjugate Vaccination during Adjuvant Chemotherapy in Gastric and Colorectal Cancer: A Randomized Controlled Trial. 
  • Improving preventive service delivery through office systems. 
  • Induction of immune responses to HIV-1 by canarypox virus (ALVAC) HIV-1 and gp120 SF-2 recombinant vaccines in uninfected volunteers. NIAID AIDS Vaccine Evaluation Group. 
  • Influenza vaccine immunogenicity in 6- to 23-month-old children: are identical antigens necessary for priming? 
  • Intradermal HIV-1 DNA Immunization Using Needle-Free Zetajet Injection Followed by HIV-Modified Vaccinia Virus Ankara Vaccination Is Safe and Immunogenic in Mozambican Young Adults: A Phase I Randomized Controlled Trial. 
  • Japanese Encephalitis Vaccine: Recommendations of the Advisory Committee on Immunization Practices. 
  • Kinetics of TCR use in response to repeated epitope-specific immunization. 
  • Large injection site reactions after a second dose of varicella vaccine. 
  • Lessons from a multisite international trial in the Caribbean and South America of an HIV-1 Canarypox vaccine (ALVAC-HIV vCP1452) with or without boosting with MN rgp120. 
  • Magnitude and breadth of the neutralizing antibody response in the RV144 and Vax003 HIV-1 vaccine efficacy trials. 
  • Maternal determinants of timely vaccination coverage among infants in rural Bangladesh. 
  • Measuring immunization coverage among preschool children: past, present, and future opportunities. 
  • Melanoma patient antibody responses to melanoma tumor-associated antigens defined by murine monoclonal antibodies. 
  • Missed opportunities for adolescent vaccination, 2006-2011. 
  • Modified Vaccinia Ankara Virus Vaccination Provides Long-Term Protection against Nasal Rabbitpox Virus Challenge. 
  • Modulation of immunologic responses to HIV-1MN recombinant gp160 vaccine by dose and schedule of administration. National Institute of Allergy and Infectious Diseases AIDS Vaccine Evaluation Group. 
  • On-time vaccine receipt in the first year does not adversely affect neuropsychological outcomes. 
  • Open-Label Pilot Study to Compare the Safety and Immunogenicity of Pentavalent Rotavirus Vaccine (RV5) Administered on an Early Alternative Dosing Schedule with Those of RV5 Administered on the Recommended Standard Schedule. 
  • Over five-year follow-up of Oka/Merck varicella vaccine recipients in 465 infants and adolescents. 
  • Pediatricians' preferences for infant meningococcal vaccination. 
  • Perspective on live varicella vaccine. 
  • Poliovaccine policy--time for a change. 
  • Practical Approaches to Optimize Adolescent Immunization. 
  • Prevention and Control of Seasonal Influenza with Vaccines: Recommendations of the Advisory Committee on Immunization Practices - United States, 2017-18 Influenza Season. 
  • Prevention and Control of Seasonal Influenza with Vaccines: Recommendations of the Advisory Committee on Immunization Practices - United States, 2019-20 Influenza Season. 
  • Prevention and Control of Seasonal Influenza with Vaccines: Recommendations of the Advisory Committee on Immunization Practices-United States, 2018-19 Influenza Season. 
  • Prevention and control of seasonal influenza with vaccines: recommendations of the Advisory Committee on Immunization Practices (ACIP) -- United States, 2014-15 influenza season. 
  • Randomized trial to determine safety and immunogenicity of two strategies for hepatitis B vaccination in healthy urban adolescents in the United States. 
  • Reactions of pediatricians to a new Centers for Disease Control recommendation for universal immunization of infants with hepatitis B vaccine. 
  • Recommendations for Prevention and Control of Influenza in Children, 2018-2019. 
  • Recommended Adult Immunization Schedule, United States, 2020. 
  • Recommended Childhood and Adolescent Immunization Schedule-United States, 2017. 
  • Recommended Childhood and Adolescent Immunization Schedule: United States, 2020. 
  • Recommended Childhood and Adolescent Immunization Schedules: United States, 2019. 
  • Recommended Immunization Schedule for Adults Aged 19 Years or Older, United States, 2018. 
  • Reimmunization to pneumococcus in patients with sickle cell disease: do they or don't they respond? 
  • SIVmac239 MVA vaccine with and without a DNA prime, similar prevention of infection by a repeated dose SIVsmE660 challenge despite different immune responses. 
  • Safety and Immunogenicity of DTaP5-IPV Compared With DTaP5 Plus IPV as the Fifth Dose in Children 4-6 Years of Age. 
  • Safety and Immunogenicity of Sequential Rotavirus Vaccine Schedules. 
  • Safety and immunogenicity of 2009 pandemic H1N1 influenza vaccination in perinatally HIV-1-infected children, adolescents, and young adults. 
  • Safety and immunogenicity of a canarypox-vectored human immunodeficiency virus Type 1 vaccine with or without gp120: a phase 2 study in higher- and lower-risk volunteers. 
  • Safety and immunogenicity of a candidate HIV-1 vaccine in healthy adults: recombinant glycoprotein (rgp) 120. A randomized, double-blind trial. NIAID AIDS Vaccine Evaluation Group. 
  • Safety and immunogenicity of a high-titered canarypox vaccine in combination with rgp120 in a diverse population of HIV-1-uninfected adults: AIDS Vaccine Evaluation Group Protocol 022A. 
  • Safety and immunogenicity of a live recombinant canarypox virus expressing HIV type 1 gp120 MN MN tm/gag/protease LAI (ALVAC-HIV, vCP205) followed by a p24E-V3 MN synthetic peptide (CLTB-36) administered in healthy volunteers at low risk for HIV infection. AGIS Group and L'Agence Nationale de Recherches sur Le Sida. 
  • Safety and immunogenicity of two heterologous HIV vaccine regimens in healthy, HIV-uninfected adults (TRAVERSE): a randomised, parallel-group, placebo-controlled, double-blind, phase 1/2a study. 
  • Safety, tolerability and immunogenicity of VAQTA given concomitantly versus nonconcomitantly with other pediatric vaccines in healthy 12-month-old children. 
  • Screening of primary gp120 immunogens to formulate the next generation polyvalent DNA prime-protein boost HIV-1 vaccines. 
  • Selection of HIV vaccine candidates for concurrent testing in an efficacy trial. 
  • Significant protection against high-dose simian immunodeficiency virus challenge conferred by a new prime-boost vaccine regimen. 
  • Subtype C gp140 Vaccine Boosts Immune Responses Primed by the South African AIDS Vaccine Initiative DNA-C2 and MVA-C HIV Vaccines after More than a 2-Year Gap. 
  • The Need to Optimize Adolescent Immunization. 
  • Three-Year Durability of Immune Responses Induced by HIV-DNA and HIV-Modified Vaccinia Virus Ankara and Effect of a Late HIV-Modified Vaccinia Virus Ankara Boost in Tanzanian Volunteers. 
  • Timing of retroviral infection influences anamnestic immune response in vaccinated primates. 
  • Trivalent inactivated influenza virus vaccine given to two-month-old children: an off-season pilot study. 
  • Update on immunizations in adults. 
  • Update: ACIP Recommendations for the Use of Quadrivalent Live Attenuated Influenza Vaccine (LAIV4) - United States, 2018-19 Influenza Season. 
  • Vaccination With Heterologous HIV-1 Envelope Sequences and Heterologous Adenovirus Vectors Increases T-Cell Responses to Conserved Regions: HVTN 083. 
  • Vaccination of macaques with long-standing SIVmac251 infection lowers the viral set point after cessation of antiretroviral therapy. 
  • Vaccine coverage and adherence to EPI schedules in eight resource poor settings in the MAL-ED cohort study. 
  • Vaccine safety: medical contraindications, myths, and risk communication. 
  • Workshop on immunizations in older adults: identifying future research agendas. 
• 

  Keywords of People

  • Cunningham, Coleen Kathryn, Professor of Pediatrics, Pathology
  • Ferrari, Guido, Associate Professor of Surgery, Molecular Genetics and Microbiology
  • Kelsoe, Garnett H., James B. Duke Distinguished Professor of Immunology, Immunology
  • Weinhold, Kent James, Joseph W. and Dorothy W. Beard Distinguished Professor of Experimental Surgery, in the School of Medicine, Immunology